Chinese Journal of Pharmacovigilance ›› 2014, Vol. 11 ›› Issue (9): 561-563.
Previous Articles Next Articles
LIU Wei, LI Xin-lin CHEN Gang, SHEN Lu, DONG Duo, LIU Cui-li, WANG Ya-li
Received:
2014-06-05
Revised:
2016-02-03
Online:
2014-09-08
Published:
2016-03-02
CLC Number:
LIU Wei, LI Xin-lin CHEN Gang, SHEN Lu, DONG Duo, LIU Cui-li, WANG Ya-li. Study on the Evaluation for Quality of Adverse Drug Reaction Reports in China[J]. Chinese Journal of Pharmacovigilance, 2014, 11(9): 561-563.
[1] CFDA. 药品不良反应报告和监测管理办法[EB/OL].(2014-05-04)[2014-09-02].http://www.cfda.gov.cn/WS01/CL1031/62621.html. [2] CFDA.国家药品不良反应监测年度报告(2013年)[EB/OL].(2014-05-14)[2014-07-31]. http://www.cfda.gov.cn/WS01/CL0078/99794.html. [3] 王晓瑜,杜文民,王宏敏,等. 2005年上海市药品不良反应自发报告质量评价[J]. 中国临床药学杂志,2006,15(5):331-333. [4] 孙骏,徐厚明,李小丽. 江苏省2005年药品不良反应/事件报告表》质量分析[J]. 中国药物警戒,2006,3(4):205- 206. [5] 裴振峨,张俊,邢丽秋,等. 北京市药品不良反应报告体系质量分析[J]. 临床药物治疗杂志,2006,4(3):59- 62. [6] 田月洁,周勇,黄琳,等. 药品不良反应报告质量评价与控制的探讨[J]. 中国药物警戒, 2009,6(2):90-95. [7] 国家药品不良反应监测中心.关于发布《药品不良反应病例报告质量评估指导意见(试行)》的通知[S]. 北京,2009:4. |
[1] | JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166. |
[2] | MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin. Drug traceability coding system in China [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172. |
[3] | ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie. Adverse reaction monitoring of toothpaste in China under the new regulatory system [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222. |
[4] | GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe. Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5. |
[5] | MA Li’na, HU Xiaozhen, ZHENG Changhui, SUN Ying, ZHAO Xu, CAO Junling, XIAO Xiaohe. Visual analysis of knowledge map of toxic Chinese medicine Changshan toxicity-effect transformation based the thought of “yin du wei neng” [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 25-32. |
[6] | LIU Min, CHEN Yan, LIU Wendong, WANG Haixue. Updates and reflections on expedited reporting of safety information during drug clinical trials [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 98-101. |
[7] | TIAN Chunhua, WU Guizhi. Implementation of periodic benefit risk evaluation reports in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1382-1384. |
[8] | ZHAO Yan, LI Yao, SONG Ya’na, ZHENG Lijia, LI Dong, ZHAO Yifei, BIAN Rongrong, DONG Fang. Post-marketing active monitoring of medical devices under vigilance [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1385-1390. |
[9] | PANG Yu, LIU Bo, WU Wenyu, TIAN Yuejie, WANG Tao. Establishment of patient reporting scheme in the UK and its implications [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1259-1263. |
[10] | WU Yunxiao, YU Yuelin, WANG Shengfeng, SUN Feng, MENG Ruogu, ZHAN Siyan. Suitability assessment of real-world data in active post-marketing surveillance of vaccine safety [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1081-1089. |
[11] | JIA Jinsheng, WANG Qing, LIU Hongliang, HOU Yongfang. Evaluation index system of MAH pharmacovigilance work [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1090-1094. |
[12] | LIU Hongliang, WANG Qing, HOU Yongfang. Design and implementation of polypharmacy risk data management platform for common diseases of the elderly based on real world data [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1095-1098. |
[13] | XIA Xudong, LI Meixia, SUN Yang, YANG Shengya. Processes of remote inspection of pharmacovigilance for marketing authorization holders [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 967-970. |
[14] | LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977. |
[15] | SHEN Yanjie, WU Yiqing. Management of adverse events during clinical trials [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 982-986. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||